XML 22 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Net revenues $ 16,544 $ 15,846 $ 14,925
Cost of sales 8,481 8,200 7,952
Gross profit 8,064 7,645 6,973
Research and development expenses, net 998 953 838
Selling and marketing expenses 2,541 2,336 2,265
General and administrative expenses 1,161 1,162 1,180
Intangible assets impairments 251 350 355
Goodwill impairment 1,280 700 2,045
Other asset impairments, restructuring and other items 1,388 718 512
Legal settlements and loss contingencies 761 1,043 2,082
Other loss (income) (14) (49) (107)
Operating income (loss) (303) 433 (2,197)
Financial expenses – net 981 1,057 966
Income (loss) before income taxes (1,284) (624) (3,163)
Income taxes (benefit) 676 (7) (643)
Share in (profits) losses of associated companies – net (1) (2) (21)
Net income (loss) (1,959) (615) (2,499)
Net income (loss) attributable to non-controlling interests (320) (56) (53)
Net income (loss) attributable to Teva $ (1,639) $ (559) $ (2,446)
Earnings (loss) per share attributable to ordinary shareholders:      
Basic $ (1.45) $ (0.5) $ (2.2)
Diluted $ (1.45) $ (0.5) $ (2.2)
Weighted average number of shares (in millions):      
Basic 1,131 1,119 1,110
Diluted 1,131 1,119 1,110